Cancer vaccination: Manipulation of immune responses at old age

Mechanisms of Ageing and Development

Volumn 130, Issue 1-2, 2009, Pages 67-75

  Gravekamp, Claudia ^a   Kim, Sun Hee ^a   Castro, Francisco ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Aging; Cancer vaccines; Immunotherapy; Impaired T cell responses

Indexed keywords

ANTINEOPLASTIC AGENT; APC; CANCER VACCINE; CD28 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 RESTRICTED HUMAN PAPILLOMA VIRUS PEPTIDE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LIPOSOME; MAGE B VACCINE; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADENOCARCINOMA; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DAMAGE; CELL FUNCTION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; GENE VECTOR; GROUPS BY AGE; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; METASTASIS; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROSTATE CANCER; SENESCENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; UTERINE CERVIX CARCINOMA;

AGED; AGING; ANIMALS; CANCER VACCINES; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 58149330785     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2008.05.003     Document Type: Article

References (81)

1. Agrawal A., Agrawal S., Cao J.N., et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinisitide 3-kinase-signaling pathway. J. Immunol. 178 (2007) 6912-6922
2. Akbasak A., Oldfield E.H., and Saris S.C. Expression and modulation of major histocompatibility antigens on murine brain tumors in vitro. J. Neurosurg. 75 (1991) 922-929
3. Baron-Bodo V., Doceur P., Levebre M.L., et al. Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiology 210 (2005) 267-277
4. Bella D., Bierti L., Presicce P., et al. Peripheral blood dendritic cells and monocytes are differentially regulated in the elderly. Clin. Immunol. 122 (2007) 220-228
5. Blieden T.M., McAdam A.J., and Foresman M.D. Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors. Int. J. Cancer Suppl. 6 (1991) 82-89
6. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3 (2003) 253-257
7. Chen M.L., Pittet M.J., Gorelik L., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. 102 (2005) 419-424
8. Chen A., Liu S., Park D., et al. Depleting intratumoral CD4 + CD25 + regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adaptive T cell transfer. Cancer Res. 67 (2007) 1291-1298
9. Corver W.E., Koopman L.A., van der Aa J., et al. Four-color multiparameter DNA flow cytometry to study phenotypic intratumor heterogeneity in cervical cancer. Cytometry 39 (2000) 96-107
10. Curiel T.J. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117 (2007) 1167-1174
11. Daftarian P.M., Mansour M., Pohajdak B., et al. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J. Translational Med. 5 (2007) 1-9
12. Effros R.B. Replicative senescence of CD8 T cells: effect on human aging. Exp. Gerontol. 39 (2004) 517-524
13. Filaci G., Fravega M., Negrini S., et al. Nonantigen-specific CD8 + suppressor lymphocytes originate from CD8 + CD28-T cells and inhibit both T cell proliferation and CTL function. Hum. Immunol. 65 (2004) 142-156
14. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 7 (2000) 1027-1034
15. Gajewski T.F., Meng Y., and Harlin H. Immune suppression in tumor microenvironment. J. Immunother. 29 (2006) 233-240
16. Garrido F., Ruiz-Cabello F., Cabrera T., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18 (1997) 89-95
17. Gavin M.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (2007) 771-775
18. George A.J.T., and Ritter M.A. Thymic involution with ageing: obsolescence or good houskeeping?. Immunol. Today 17 (1996) 267-272
19. Goronzy J.J., Fulbright J.W., Crowson C.S., et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 75 (2001) 12182-12187
20. + lymphocytes by autologous tumor cells. Int. J. Cancer 46 (1990) 152-154
21. Gravekamp C. Tailoring cancer vaccines to the elderly: the importance of suitable mouse models. MAD 122 (2001) 1087-1105
22. Gravekamp C. Cancer vaccines in old age. Exp. Gerontol. 42 (2007) 441-450
23. Gravekamp, C., in press. Cancer immunotherapy and aging: lessons from the mouse. In: Fulop, T., Pawelec, G., Franceschi, C., Hirokawa, K. (Eds.), Handbook on Immunosenescence: Basic Understanding and Clinical Applications. Springer.
24. Gravekamp C., Leal B., Denny A., Bahar R., Lampkin S., Castro F., Moore D., and Reddick R. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model 4T1. Cancer Immunol. Immunother. 57 (2008) 1067-1077
25. Gregg R., Smith C.M., Clark F.J., et al. The number of human peripheral blood CD4 + CD25 high regulatory T cells increases with age. Clin. Exp. Immunol. 140 (2005) 540-546
26. Grubeck-Loebenstein B. Changes in the aging immune system. Biologicals 25 (1997) 205-208
27. Hwu P., Du M.X., Lapointe R., et al. Indolamine 2.3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164 (2000) 3596-3599
28. Itzhaki O., Kaptzan T., Skutelsky E., et al. Age-adjusted antitumoral therapy based on the demonstration of increased apoptosis as a mechanism underlying the reduced malignancy of tumors in the aged 1688 (2004) 145-159
29. Jonuleit H., Schmitt E., Steinbrink K., et al. Dendritic cells as a tool to induce anergic and regulatory T-cells. Trends Immunol. 22 (2001) 394-400
30. Kim R., Manabu E., Tanabe E., et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66 (2006) 5527-5536
31. Kobie J.J., Wu R.S., Kurt R.A., et al. Transforming growth factor beta inhibits the antigen-presenting functions and anti-tumor activity of dendritic cell vaccines. Cancer Res. 63 (2003) 1860-1864
32. Koyama S., Maruyama T., Adachi S., et al. Expression of costimulatory molecules. B7-1 and B7-2 on human gastric carcinoma. J. Can. Res. Clin. Oncol. 124 (1998) 383-388
33. Kuroda E., and Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandine E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J. Immunol. 170 (2003) 757-764
34. Loo D.T., Chalupny N.J., Bajorath J., et al. Analysis of 4-IBBL and laminin binding to murine 4-IBB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-IBB. J. Biol. Chem. 272 (1997) 6448-6456
35. Lung T.L., Sauerwein-Teissl M., Parson W., et al. Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells. Vaccine 18 (2000) 1606-1612
36. Lusgarten J., Dominguez A.L., and Thomas M. Aged mice develop protective anti-tumor responses with appropriate costimulation. J. Immunol. 173 (2004) 4510-4515
37. Mahnke K., Schonfeld K., Fondel S., et al. Depletion of CD4 + CD25 + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120 (2007) 2723-2733
38. Maker A.V., Attia P., and Rosenberg S.A. Analysis of the cellular mechanism of anti-tumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175 (2005) 7746-7754
39. Masucci M.G., Torsteindottir S., Colombani J., et al. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 4567-4571
40. Maurer C.A., Friess H., Kretschmann B., et al. Over-expression of ICAM-1. VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int. J. Cancer 79 (1998) 76-81
41. McElhaney J.E., Meneilly G.S., Lechelt K.E., et al. Split-virus influenza vaccines: do they provide adequate immunity in the elderly?. Gerontology 49 (1994) M37-43
42. Melero I., Shuford W.W., Newby S.A., et al. Monoclonal antibodies against the 4-IBB T-cell activation molecule eradicate established tumors. Nat. Med. 3 (1997) 682-685
43. Miller R.A. The aging immune system: primer and prospectus. Science 273 (1996) 70-74
44. Muss H.B. Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. J. Natl. Cancer Inst. Monogram 30 (2001) 52-55
45. Nair S.K., Heiser A., Bockowski D., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 6 (2000) 1011-1017
46. Nardin A., Levebre M.L., Labroquere K., et al. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets 6 (2006) 123-133
47. Nasi M., Troiano L., Lugli E., et al. Thymic output and functionality of the IL-7/IL-7 receptor system in centenarans: implications for neolymphogenesis at the limit of human life. Aging Cell 5 (2006) 167-175
48. Nishioka T., Shimizu J., Yamazaki S., et al. CD4 + CD25 + Fox3 + T cells and CD4 + CD25-Fox3 + T cells in aged mice. J. Immunol. 176 (2006) 6586-6593
49. Park S.J., Nakagawa T., Kitamura H., et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173 (2004) 3844-3854
50. Pedrinaci S., Algarra I., Garcia L.A., et al. Selective upregulation of MHC class I expression in metastatic colonies derived from tumor clones of a murine fibrosarcoma. Int. J. Clin. Lab. Res. 29 (1999) 166-173
51. Provinciali M., Argentati K., and Tibaldi A. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther. 7 (2000) 624-632
52. Provinciali M., Smorlesi A., Donnini A., et al. Low effectiveness of DNA vaccination against HER2/neu in aging. Vaccine 21 (2003) 843-848
53. Quyang Q., Cicek G., Westendorp R.G.J., et al. Reduced IFNγ production in elderly people following in vitro stimulation with influenza vaccine and endotoxin. Mech. Ageing Dev. 121 (2000) 131-137
54. Ouyang G.F., Saio M., Suwa T., et al. Interleukin-2 augmented activation of tumor-associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int. J. Oncol. 28 (2006) 1201-1208
55. Renshaw M., Rocjwell J., Engleman C., et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol. 169 (2002) 4697-4701
56. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells express IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995) 1151-1164
57. Saslow D., Runowicz C.D., Solomon D., et al. American Society Guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52 (2002) 342-362
58. Sauerwein-Teissl M., Schonitzer D., and Grubeck-Loebenstin B. Dendritic cell responsiveness to stimulation with influenza vaccine is unimpaired in old age. Exp. Gerontol. 33 (1998) 625-631
59. Sauerwein-Teissl M., Lung T.L., Marx F., et al. Lack of antibody production following immunization in old age:association with CD8 + CD28-T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J. Immunol. 168 (2002) 5893-5899
60. Schreiber H. Tumor immunology. In: Paul W. (Ed). Fundamental Immunology. 4th Ed. (1998), Lippencott-Raven 1237-1270
61. Sengupta S., den Boon J.A., Chen I.H., et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 66 (2006) 7999-8006
62. Sharma S., Domiguez A.L., and Lusgarten J. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp. Gerontol. 41 (2006) 78-84
63. Shi W., Li L., Shi X., et al. Inhibition of nuclear factor-kB activation is essential for membrane-associated TNF-alpha-induced apoptosis in HL-60 cells. Immunol. Cell Biol. 84 (2006) 366-373
64. Shimizu J., Yamzaki S., and Sakaguchi S. Induction of tumor immunity by removing CD4 + CD25 + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999) 5211-5218
65. Sica A., Saccani A., Bottazzi B., et al. Autocrine production of IL-10 mediates defective IL-12 production and NFk-B activation in tumor-associated macrophages. J. Immunol. 164 (2000) 762-767
66. Sprecher E., Becker Y., Kraal G., et al. Effect of aging on the epidermal dendritic cell population in C57Bl/6J mice. J. Invest. Dermatol. 94 (1990) 247-253
67. Stacy S., Infante A.J., Wall K., et al. Recall immune memory: a new tool for generating late onset autoimmune myasthenia gravis. Mech. Ageing Dev. 124 (2003) 931-940
68. Starace D., Riccioli A., D'Alessio A., et al. Characterization of signaling pathways leading to Fas expression induced by TNFα: pivotal role of NF-κB. FASEB 19 (2004) 473-475
69. Steffens C.M., Alharthi L., Shott S., et al. Evaluation of thymopoiesis using T cell receptor excision circles (TRECs): differential correlation between adult and pediatric TRECs and naive phenotypes. Clin. Immunol. 97 (2000) 95-101
70. Sunderkotter C., Laden H., and Luger T.A. Aging and the skin immune system. Arch. Dermatol. 133 (1997) 1256-1262
71. Sypniewska R.K., Hoflack L., Tarango M., et al. Prevention of metastases with Mage-b vaccine in a mouse breast tumor model: potential for breast cancer therapy. Breast Cancer Res. Treat. 91 (2005) 19-28
72. Tamir A., Eisenbraun M.D., Garcia G.G., et al. Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell/APC interaction. J. Immunol. 165 (2000) 1243-1251
73. Tan J.T., Dudl E., LeRoy E., et al. IL-7 is critical for homeostatic proliferation and survival of naïve T cells. Proc. Natl. Acad. Sci. 98 (2001) 8732-8737
74. Tanaka H., Tanaka J., Kjaergaard J., et al. Depletion of CD4 + CD25 + regulatory T cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25 (2002) 207-217
75. Utsuyama M., Hirokawa K., Kurashima C., et al. Differential age-change in the number of CD4 + CD45RA + and CD4 + CD29 + T cell subsets in human peripheral blood. Mech. Ageing Dev. 63 (1992) 57-68
76. Van Duin D., Mohanty S., Thomas V., et al. Age-associated defect in human TLR-1/2 function. J. Immunol. 15 (2007) 970-975
77. Van Elsas A., Hurwitz A.A., and Allison P. Combination of immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-1) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 3 (1999) 355-366
78. Wack A., Cossarizza A., Heltai S., et al. Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4 + and CD8 + subsets. Int. Immunol. 10 (1998) 1281-1288
79. Wan Y.Y., and Flavel R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445 (2007) 766-770
80. Weber J.S., and Rosenberg S.A. Effects of murine tumor class I major histocompatibility complex expression on anti-tumor activity of tumor-infiltrating lymphocytes. J. Natl. Cancer Inst. 82 (1990) 755-761
81. Zou W. Regulatory T cell, tumour immunity and immunotherapy. Nat. Rev./Immunol. 6 (2006) 295-307